153 related articles for article (PubMed ID: 17189034)
1. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins.
Gregori L; Gurgel PV; Lathrop JT; Edwardson P; Lambert BC; Carbonell RG; Burton SJ; Hammond DJ; Rohwer RG
Lancet; 2006 Dec; 368(9554):2226-30. PubMed ID: 17189034
[TBL] [Abstract][Full Text] [Related]
2. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands.
Gregori L; Lambert BC; Gurgel PV; Gheorghiu L; Edwardson P; Lathrop JT; Macauley C; Carbonell RG; Burton SJ; Hammond D; Rohwer RG
Transfusion; 2006 Jul; 46(7):1152-61. PubMed ID: 16836562
[TBL] [Abstract][Full Text] [Related]
3. Removal of exogenous prion infectivity in leukoreduced red blood cells unit by a specific filter designed for human transfusion.
Lescoutra-Etchegaray N; Sumian C; Culeux A; Durand V; Gurgel PV; Deslys JP; Comoy EE
Transfusion; 2014 Apr; 54(4):1037-45. PubMed ID: 24117735
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood.
Gregori L; McCombie N; Palmer D; Birch P; Sowemimo-Coker SO; Giulivi A; Rohwer RG
Lancet; 2004 Aug 7-13; 364(9433):529-31. PubMed ID: 15302197
[TBL] [Abstract][Full Text] [Related]
5. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
Berardi VA; Cardone F; Valanzano A; Lu M; Pocchiari M
Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
[TBL] [Abstract][Full Text] [Related]
6. Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate.
Diez JM; Caballero S; Belda FJ; Otegui M; Gajardo R; Jorquera JI
Haemophilia; 2009 Nov; 15(6):1249-57. PubMed ID: 19563480
[TBL] [Abstract][Full Text] [Related]
7. Prion protein and the red cell.
Anstee DJ
Curr Opin Hematol; 2007 May; 14(3):210-4. PubMed ID: 17414209
[TBL] [Abstract][Full Text] [Related]
8. Capacity of the manufacturing process of Flebogamma(®) DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent.
Diez JM; Caballero S; Belda F; Otegui M; Gajardo R; Jorquera JI
Biologicals; 2010 Nov; 38(6):670-4. PubMed ID: 20863716
[TBL] [Abstract][Full Text] [Related]
9. Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates.
Sowemimo-Coker SO; Pesci S; Andrade F; Kim A; Kascsak RB; Kascsak RJ; Meeker C; Carp R
Vox Sang; 2006 May; 90(4):265-75. PubMed ID: 16635068
[TBL] [Abstract][Full Text] [Related]
10. An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease.
Cervia JS; Sowemimo-Coker SO; Ortolano GA; Wilkins K; Schaffer J; Wortham ST
Transfus Med Rev; 2006 Jul; 20(3):190-206. PubMed ID: 16787827
[TBL] [Abstract][Full Text] [Related]
11. Assessment of prion reduction filters in decreasing infectivity of ultracentrifuged 263K scrapie-infected brain homogenates in "spiked" human blood and red blood cells.
Cardone F; Sowemimo-Coker S; Abdel-Haq H; Sbriccoli M; Graziano S; Valanzano A; Berardi VA; Galeno R; Puopolo M; Pocchiari M
Transfusion; 2014 Apr; 54(4):990-5. PubMed ID: 23915063
[TBL] [Abstract][Full Text] [Related]
12. A sensitive and quantitative assay for normal PrP in plasma.
Gregori L; Gray BN; Rose E; Spinner DS; Kascsak RJ; Rohwer RG
J Virol Methods; 2008 May; 149(2):251-9. PubMed ID: 18339433
[TBL] [Abstract][Full Text] [Related]
13. Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter.
Sowemimo-Coker S; Kascsak R; Kim A; Andrade F; Pesci S; Kascsak R; Meeker C; Carp R; Brown P
Transfusion; 2005 Dec; 45(12):1839-44. PubMed ID: 16371036
[TBL] [Abstract][Full Text] [Related]
14. Candidate cell substrates, vaccine production, and transmissible spongiform encephalopathies.
Piccardo P; Cervenakova L; Vasilyeva I; Yakovleva O; Bacik I; Cervenak J; McKenzie C; Kurillova L; Gregori L; Pomeroy K; Asher DM
Emerg Infect Dis; 2011 Dec; 17(12):2262-9. PubMed ID: 22172513
[TBL] [Abstract][Full Text] [Related]
15. [Biology of non-conventional transmissible agents or prions].
Dormont D
Rev Neurol (Paris); 1998 Feb; 154(2):142-51. PubMed ID: 9773035
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis and transfusion risk of transmissible spongiform encephalopathies.
Brown P
Dev Biol (Basel); 2005; 120():27-33. PubMed ID: 16050152
[TBL] [Abstract][Full Text] [Related]
17. Removal of prion infectivity by affinity ligand chromatography during OctaplasLG® manufacturing--results from animal bioassay studies.
Heger A; Bailey A; Neisser-Svae A; Ertl M; Römisch J; Svae TE
Vox Sang; 2012 May; 102(4):294-301. PubMed ID: 22070802
[TBL] [Abstract][Full Text] [Related]
18. Expression of cellular prion protein on blood cells: potential functions in cell physiology and pathophysiology of transmissible spongiform encephalopathy diseases.
Vostal JG; Holada K; Simak J
Transfus Med Rev; 2001 Oct; 15(4):268-81. PubMed ID: 11668434
[TBL] [Abstract][Full Text] [Related]
19. Prion encephalopathies of animals and humans.
Prusiner SB
Dev Biol Stand; 1993; 80():31-44. PubMed ID: 8270114
[TBL] [Abstract][Full Text] [Related]
20. A prion reduction filter does not completely remove endogenous prion infectivity from sheep blood.
McCutcheon S; Alejo Blanco AR; Tan BC; González L; Martin S; Mallinson G; Appleford NE; Turner ML; Manson JC; Houston EF
Transfusion; 2015 Sep; 55(9):2123-33. PubMed ID: 26032915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
